SCHEMBL4331501

SCHEMBL4331501

COCCCN(N=Cc1ccc(-c2ccc(Cl)c(Cl)c2)o1)C(N)=S

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.53
ALDH1A1 P00352 6/20 0.53
HPGD P15428 5/20 0.53
MEN1 O00255 5/20 0.53
MAPT P10636 4/20 0.53
NPSR1 Q6W5P4 3/20 0.53
HTT P42858 1/20 0.53
POLB P06746 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 1/20 0.40
BLM P54132 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PHGDH O43175 2/20 0.38
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PKM P14618 1/20 0.38
ALOX12 P18054 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
TP53 P04637 1/20 0.37
GCGR P47871 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4331661 0.86 KMT2A (0.56) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL4331665 0.86 KMT2A (0.56) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL4341232 0.86 KMT2A (0.58) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL4455856 0.84 KMT2A (0.60) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL13887398 0.84 KMT2A (0.57) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL4331630 0.83 MAPT (0.39) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL4329284 0.80 HPGD (0.52) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL4329288 0.80 HPGD (0.52) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL4326666 0.79 HPGD (0.51) KMT2AALDH1A1HPGDMEN1MAPT
SCHEMBL6445038 0.79 KMT2A (0.63) KMT2AALDH1A1HPGDMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KMT2A 3988/4885ALDH1A1 1459/4885HPGD 1646/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KMT2A 3714/4885ALDH1A1 1173/4885HPGD 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.